semaglutide sexual function study Are Side Effects Emerging With GLP-1 Agonists? Male sexual dysfunction associated with

Eli Lilly's tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, is being studied in adolescents (SURMOUNT-TEENS), but similarly has no active trial in children under 12

[3] Clinical trials of tirzepatide, including the SURPASS and SURMOUNT programs involving over 10,000 participants, have not demonstrated a signal for increased incidence of thyroid cancer or thyroid nodules compared to placebo or active comparators during treatment periods up to two years

Res Rev

The label advises considering increased clinical or laboratory monitoring with concomitant oral medications

The program remains a critical funding source for safety-net hospitals and the patients they serve

Semaglutide can slow gastric emptying, which may delay your colon's response to bowel-cleansing solutions